LOGIN  |  REGISTER
Recursion
Chimerix

RadNet to Present at the BofA Securities 2023 Leveraged Finance Conference on November 28, 2023

November 27, 2023 | Last Trade: US$72.25 0.18 -0.25

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2023 Leveraged Finance Conference in Boca Raton, FL on Tuesday, November 28, 2023 at 11:10 a.m. Pacific Time (2:10 p.m. Eastern Time).

There will be simultaneous and archived webcasts available here and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.

Details for RadNet's Presentation:
Date:   Tuesday, November 28, 2023
Time: 11:10 a.m. Pacific Time (2:10 p.m. Eastern Time)
Location: Boca Raton Resort, Boca Raton, FL

About RadNet, Inc.

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees. For more information, visit http://www.radnet.com

CONTACT:

RadNet, Inc.

Mark Stolper, 310-445-2800

Executive Vice President and Chief Financial Officer

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page